Physician profile
Thomas Joseph
NPI 1205900222
$5,077.36
in general payments reported to CMS, 2019-2025
33 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $598 · 2021: $359 · 2022: $905 · 2023: $676 · 2024: $1,016 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.78 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $724.11 | 2019-2025 | Repatha, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $721.20 | 2020-2025 | Verquvo, Steglatro, Capvaxive |
| Novartis Pharmaceuticals Corporation | $607.46 | 2019-2025 | |
| Abbott Laboratories | $458.95 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $428.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $323.30 | 2019-2024 | Xarelto |
| Daiichi Sankyo INC. | $248.39 | 2021-2025 | Injectafer |
| Glaxosmithkline, LLC. | $241.53 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $167.79 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.03 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $97.94 | 2022-2024 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $88.98 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $71.48 | 2024-2025 | Watchman Flx |
| Amarin Pharma, INC. | $66.97 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $60.62 | 2023-2024 | Assure Wcd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $58.97 | 2023-2024 | Camzyos |
| Pfizer INC. | $58.03 | 2021-2023 | |
| United Therapeutics Corporation | $57.62 | 2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $56.72 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $53.04 | 2023-2024 | Inpefa |
| Baxter Healthcare | $45.98 | 2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Esperion Therapeutics, INC. | $39.92 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.50 | 2024-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $23.36 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $23.04 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $21.94 | 2025 | |
| Sanofi Pasteur INC. | $21.66 | 2022 | |
| Bridgebio Pharma, INC. | $20.26 | 2025 | Attruby |
| Abbvie INC. | $20.00 | 2021 | |
| Sumitomo Pharma America, INC. | $19.64 | 2025 | Gemtesa |
| Exact Sciences Corporation | $18.39 | 2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $16.79 | 2023 | Inspire |
| Bardy Diagnostics, INC. | $16.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.